Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting.
Chronic Pseudomonas aeruginosa infection
Inhaled antibiotics
Levofloxacin solution
Pulmonary function test
exacerbation rate
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
17
11
2020
revised:
04
03
2021
accepted:
06
03
2021
pubmed:
9
6
2021
medline:
10
2
2022
entrez:
8
6
2021
Statut:
ppublish
Résumé
Levofloxacin inhalation solution is the most recently approved inhaled antibiotic in Europe and Canada for adult cystic fibrosis patients. Its efficacy and safety have been assessed in randomized controlled trials. Our aim was to evaluate real life experience and outcomes in our treatment centre. We evaluated the efficacy of inhaled levofloxacin solution in 86 patients with cystic fibrosis in terms of the following outcome parameters: changes in %-predicted forced expiratory volume in one second (FEV Change in FEV In patients with cystic fibrosis, inhaled levofloxacin solution has the potential to improve FEV
Sections du résumé
BACKGROUND
Levofloxacin inhalation solution is the most recently approved inhaled antibiotic in Europe and Canada for adult cystic fibrosis patients. Its efficacy and safety have been assessed in randomized controlled trials. Our aim was to evaluate real life experience and outcomes in our treatment centre.
METHODS
We evaluated the efficacy of inhaled levofloxacin solution in 86 patients with cystic fibrosis in terms of the following outcome parameters: changes in %-predicted forced expiratory volume in one second (FEV
RESULTS
Change in FEV
CONCLUSIONS
In patients with cystic fibrosis, inhaled levofloxacin solution has the potential to improve FEV
Identifiants
pubmed: 34099405
pii: S1569-1993(21)00051-5
doi: 10.1016/j.jcf.2021.03.002
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Levofloxacin
6GNT3Y5LMF
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035-1039Informations de copyright
Copyright © 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Carsten Schwarz received a research grant from Chiesi and he has given lectures during scientific conferences and advisory boards and received financial support by Chiesi for these activities. Claudia Grehn, Svenja Temming, Frederik Holz, Patience Ndidi Eschenhagen have no conflict of interest.